$AMTX

Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart

Aemetis reported Q2 2026 revenue of $62.7 million, up $10.5 million (20%) from Q2 2025, including $8.6 million from Section 45Z tax credits. Operating income improved by $16.4 million, net loss narrowed to $9.4 million, and adjusted EBITDA rose to $9.7 million. The company is pursuing refinancing and financing for its Keyes ethanol and Dairy RNG projects, and is considering an IPO for its India unit.

Original reporting
Published Aug 6, 2026, 5:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 5:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart — source image
Decision brief

The 30-second read

$AMTXNeutralMed
01

Why it matters

Traders can reassess near-term risk versus turnaround progress using the disclosed revenue growth, operating income improvement, and the company’s stated financing initiatives amid leverage concerns.

02

Market read

Q2 results and financing/IPO catalysts can move the stock, but leverage, low cash, and potential dilution remain key swing factors.

03

What to watch

Weighted average shares increased to 70.9M, implying dilution risk; financing progress (refinancing, IPO) is still conditional and could shift timing or terms.

Relevance 7/10Novelty 7/10Timing: reported Q2 2026 results on 2026-08-06

Background

The article summarizes Aemetis’ Q2 2026 financial performance across California Ethanol and Dairy RNG, and outlines a multi-track financing plan including potential Keyes refinancing and an India subsidiary IPO.

Company-level read

Ticker impact

$AMTXNeutralMedium confidence
Context

Aemetis reported Q2 2026 revenue of $62.7M (+20% YoY), improved operating income, and narrowed net loss, plus financing and IPO progress.

Expected impact

Near-term trading likely two-sided: upside from revenue and EBITDA improvement, offset by refinancing risk and large stockholder deficit.

Evidence & confidence

The article provides concrete quarterly financials and highlights a multi-track financing plan, including potential Keyes refinancing and an India subsidiary IPO, which can drive sentiment but also raises dilution/debt risk.

Market effects

Biofuels and RNG operators may see read-across interest in Section 45Z credit contribution and project execution timelines.

California ethanol production and RNG scaling progress could influence regional renewable fuel sentiment.

Limited direct global impact; story is primarily company-specific within US renewable fuels.

Counterpoint

Improved Adjusted EBITDA and narrowed net loss may not translate into sustainable cash generation given the very large stockholders’ deficit and low cash balance.

Key entities

  • Aemetis, Inc.

    Reported Q2 2026 results, including $62.7M revenue, improved operating income, narrowed net loss, and Adjusted EBITDA of $9.7M, plus financing and IPO-related updates.

  • Keyes ethanol plant

    Planned MVR upgrade expected to be operational in 2026, and potential long-term refinancing is part of the financing plan.

  • Universal Biofuels Private Limited

    India subsidiary for which Aemetis retained advisors and is pursuing a potential IPO.

Related articles

$AMTXMedAI 8/10

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) reported Q2 2026 revenue of $62.7M, up 20% YoY, with operating income of $5.8M, reversing a prior-year loss. Growth was driven by ethanol and renewable natural gas segments. Adjusted EBITDA improved to $9.7M from -$5.8M. Management highlighted projects like mechanical vapor recompression and LCFS pathway approvals, but noted risks from uncertain emissions rates and feedstock constraints.

$AMTXMed

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) Q2 2026 earnings call said consolidated revenue rose 20% year over year, operating income improved by $16.4 million, and adjusted EBITDA increased by $15.5 million versus Q2 2025. The company cited CARB approval of 7 LCFS pathways and pending approvals for 6 digesters, plus ethanol projects including a $32 million annual cash flow MVR system. India biodiesel revenue was $2.5 million, with expected $17 million from new allocations.

$AMTXMed

AEMETIS, INC (AMTX): Results of Operations and Financial Condition

AEMETIS, INC (AMTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Company Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemetis.com Aemetis Reports Second Quarter 2026 Financial Results Revenue Growth o

$AMTXMed

Aemetis stock rises on India biodiesel supply deal

Aemetis Inc (NASDAQ:AMTX) shares rose 4.3% after its India unit, Universal Biofuels, secured about $17 million in biodiesel supply contracts. Over three months it will deliver more than 18 million liters to India’s three government-owned Oil Marketing Companies, supporting a policy to raise biodiesel blending to 5% by 2030. Additional orders are expected through 2026.